Eli Lilly (LLY) shares phase 3 data on weight loss drug retatrutide

Eli Lilly (LLY) released phase 3 clinical trial data for retatrutide, a triple agonist designed for weight loss. The drug demonstrated significant efficacy in reducing body weight among participants, but specific numerical results were not disclosed in the announcement. This development is crucial as it highlights LLY's commitment to expanding its product portfolio in the obesity treatment space. The market could respond positively if further details indicate strong potential for retatrutide in the pharmaceutical market.